Gilead poaches B-MS exec as new CCO

US biotech major Gilead Sciences (Nasdaq: GILD) today announced that Johanna Mercier will join the company as chief commercial officer, and will become a member of the company’s senior leadership team.

Ms Mercier will assume responsibility for the company’s commercial operations effective July 1. Laura Hamill, executive vice president worldwide commercial operations, will be departing from Gilead.

Ms Mercier is a proven leader who brings to Gilead deep experience in worldwide and senior operational roles in geographies around the globe. She has held leadership positions in therapeutic areas including oncology, inflammation and neuroscience. She joins Gilead from Bristol-Myers Squibb (NYSE: BMY), where she most recently served as president and head of the company’s Large Markets division, which includes the USA, France, Germany and Japan. Over the course of her career, she has helped drive growth across key markets, pioneered innovative access strategies in the United States and Europe and helped establish new standards of care for people with cancer.